MEDIFAST INC
No enriched coverage for $MED in the last 7 days.
Medifast (MED) announced its MED 3.0 strategy, shifting focus to metabolic health under the Trilivy brand. The company aims to return to profitability by Q4 2026 through cost savings and revenue growth initiatives. MED's shares have gained 17.5% in six months, trading at a forward P/S ratio of 0.50. Analysts expect a 26.8% decline in current-year earnings but 54.8% growth next year.
On August 28, 2026, 183 insider stock purchases were reported. Notable transactions include Klarna Group's CEO buying 692,506 shares for $9.95M, Medifast's Kiai Parsa purchasing 41,975 shares for $514,747, and Regenxbio's Ciongoli buying 53,407 shares for $499,675. Hawkins' Lange and FTC Solar's Sadasivam also made significant purchases.
Kiai Parsa purchased 43,150 indirectly-held shares of MEDIFAST INC (MED) at $12.26 ($0.53M total) across 2 trades on 2026-08-26.
Recent MED coverage spans earnings, insider activity and financial news.
In the last 30 days, MED insiders filed 8 SEC Form 4 transactions — 8 purchases ($1.4M) and no sales. The most active reporter was Kiai Parsa with 8 filings.
Strategic shift may improve margins and drive top‑line growth, but execution risk remains.
Insider buying may signal confidence, modest upside potential.
The purchase signals insider confidence and may provide short‑term buying pressure.
Small insider purchase may signal confidence but limited price impact.
Insider purchase signals confidence but size is modest.
AlphAI scores every news story that mentions MED with an AI model for sentiment and relevance, and aggregates insider trades from MEDIFAST INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Medifast (MED) announced its MED 3.0 strategy, shifting focus to metabolic health under the Trilivy brand. The company aims to return to profitability by Q4 2026 through cost savings and revenue growth initiatives. MED's shares have gained 17.5% in six months, trading at a forward P/S ratio of 0.50. Analysts expect a 26.8% decline in current-year earnings but 54.8% growth next year.
2 min readOn August 28, 2026, 183 insider stock purchases were reported. Notable transactions include Klarna Group's CEO buying 692,506 shares for $9.95M, Medifast's Kiai Parsa purchasing 41,975 shares for $514,747, and Regenxbio's Ciongoli buying 53,407 shares for $499,675. Hawkins' Lange and FTC Solar's Sadasivam also made significant purchases.
1 min readKiai Parsa purchased 43,150 indirectly-held shares of MEDIFAST INC (MED) at $12.26 ($0.53M total) across 2 trades on 2026-08-26.
1 min readKiai Parsa purchased 4,329 indirectly-held shares of MEDIFAST INC (MED) at $12.00 across 2 trades on 2026-08-24.
1 min readKiai Parsa purchased 72,487 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.63 ($11.60–$11.66, $0.84M total) across 4 trades over 2026-08-19 to 2026-08-20.
1 min readMedifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.
4 min readMedifast (NYSE:MED) reported Q2 CY2026 revenue of $76.38M, down 27.6% year over year but 5.1% above expectations. Next-quarter revenue guidance was $70M at the midpoint, about 3.4% above analyst estimates. GAAP EPS loss was $0.28, worse than consensus. Shares rose 12.8% to $10.99.
3 min readMEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Second Quarter 2026 Financial Results August 3, 2026 BALTIMORE – ( BUSINESS WIRE ) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter
6 min readMedifast (NYSE: MED) will report Q2 results Monday after market hours. The prior quarter revenue was $76.04 million, down 34.3% year over year, and EPS guidance for next quarter exceeded analysts’ expectations. For the upcoming quarter, analysts expect revenue down 31.1% year over year. MED shares are down 10.9% over the past month; average price target is $12 vs $9.83.
4 min readMedifast Inc. (MED) is scheduled to report Q2 2026 earnings on Aug. 3 after the market closes, with results expected at 4:05 PM ET. The consensus estimates call for revenue of $72.70 million and EPS of -$0.65 for the quarter, according to the article.
1 min read
